---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-110971"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2026-09-25T20:10:39+00:00"
generated_at: "2026-10-12T13:22:36.320407+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NextCure seeks Delaware court validation of 2025 reverse split tied to Avere merger

## Summary
- NextCure filed a Section 205 petition on Sept. 14, 2026, in Delaware Court of Chancery seeking validation of its 1:12 reverse split filed July 10, 2025.
- The 2025 reverse split drew 18,166,577 votes for, 2,028,946 against and 6,613 abstentions; 64.76% of outstanding shares backed it, short of the 66 2/3% supermajority.
- The Delaware Court of Chancery scheduled a hearing for Nov. 6, 2026, at 3:00 p.m. ET; stockholder opposition submissions are due by Oct. 27, 2026, to the Register in Chancery.
- NextCure plans a 2026 reverse split under the supermajority standard tied to its Avere Therapeutics combination; failure could delay or block that merger.

## SEC filing metadata
- accession: 0001104659-26-110971
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2026-09-25T20:10:39+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465926110971/0001104659-26-110971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465926110971/nxtc-20260921x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-110971
- JSON: https://secwatch.observer/filing/0001104659-26-110971.json
- Plain text: https://secwatch.observer/filing/0001104659-26-110971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.